脂肪因子与结直肠癌

国际肿瘤学杂志››2015,Vol. 42››Issue (1): 67-70.doi:10.3760/cma.j.issn.1673-422X.2015.01.018

陈燕, 陈明卫

230032合肥，安徽医科大学第一附属医院内分泌科

收稿日期:2014-06-18修回日期:2014-10-08出版日期:2015-01-08发布日期:2015-01-07
通讯作者:陈明卫 E-mail:chmw1@163.com
基金资助:

中华医学会临床医学科研专项（12020320322）；安徽省科技计划（1206c0805034）

Adipokines and colorectal cancer

Chen Yan, Chen Mingwei

Department of Endocrinology, First Affiliated Hospital of Anhui Medcial University , Hefei 230032, China

Received:2014-06-18Revised:2014-10-08Online:2015-01-08Published:2015-01-07
Contact:Chen Mingwei E-mail:chmw1@163.com

摘要/Abstract

摘要：脂联素、瘦素、网膜素、内脂素均为脂肪组织细胞分泌的脂肪因子，与肥胖、胰岛素抵抗密切相关。研究发现上述脂肪因子也与结直肠癌的发生发展密切相关，有望成为结直肠癌临床诊断以及预后判断的生物学标志物。目前关于脂肪因子如何诱发结直肠癌的机制尚不清楚，仍需开展深入的研究。

陈燕, 陈明卫. 脂肪因子与结直肠癌[J]. 国际肿瘤学杂志, 2015, 42(1): 67-70.

Chen Yan, Chen Mingwei. Adipokines and colorectal cancer[J]. Journal of International Oncology, 2015, 42(1): 67-70.

［1］刘明月, 臧福才, 唐伟. 肥胖与肿瘤［J］. 国际肿瘤学杂志, 2013, 40(7): 501-503. ［2］ Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence［J］. Endocr Rev, 2012, 33(4): 547-594. ［3］ Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer［J］. Cancer Sci, 2010, 101(5): 1286-1291. ［4］ Xu XT, Xu Q, Tong JL, et al. Metaanalysis: circulating adiponectin levels and risk of colorectal cancer and adenoma［J］. J Dig Dis, 2011, 12(4): 234-244. ［5］ Wei EK, Giovannucci E, Fuchs CS, et al. Low plasm adiponectin levels and risk of colorectal cancer in men: a prospective study［J］. J Natl Cancer Inst, 2005, 97(22): 1688-1694. ［6］ Chen MW, Ye S, Zhao LL, et al. Association of palma total and highmolecularweight adiponectin with risk of colorectal cancer: an observational study in Chinese male［J］. Med Oncol, 2012, 29(5): 3129-3135. ［7］ Aleksandrova K, Boeing H, Jenab M, et al. Total and highmolecular weight adiponectin and risk of colorectal cancer: the European prospective investigation into cancer and nutrition study［J］. Carcinogenesis, 2012, 33(6): 1211-1218. ［8］ Song M, Zhang X, Wu K, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study［J］. Cancer Prev Res (Phila), 2013, 6(9): 875885. ［9］ Moon HS, Liu X, Nagel JM, et al. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice［J］. Gut, 2013, 62(4): 561-570. ［10］ Sugiyama M, Takahashi H, Hosono K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway［J］. Int J Oncol, 2009, 34(2): 339-344. ［11］ Kim AY, Lee YS, Kim KH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1andR2mediated AMPK activation［J］. Mol Endocrinol, 2010, 24(7): 1441-1452. ［12］ Kim HH, Kim YS, Kang YK, et al. Leptin and peroxisome proliferatoractivated receptor γ expression in colorectal adenoma［J］. World J Gastroenterol, 2012, 18(6): 557-562. ［13］ Paik SS, Jang SM, Jang KS, et al. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma［J］. Ann Surg Oncol, 2009, 16(2): 297-303. ［14］ Aleksandrova K, Boeing H, Jenab M, et al. Leptin and soluble leptin receptor in risk of colorectal cancer in the European prospective investigation into cancer and nutrition cohort［J］. Cancer Res, 2012, 72(20): 5328-5337. ［15］ Cong JC, Dai XW, Shen MY, et al. Expression of obesity hormone leptin in human colorectal cancer［J］. Chin J Cancer Res, 2009, 21(2): 142-146. ［16］ Stachowicz M, Mazurek U, NowakowskaZajdel E, et al. Leptin and its receptors in obese patients with colorectal cancer［J］. J Biol Regul Homeost Agents, 2010, 24(3): 287-295. ［17］ Wang D, Chen J, Chen H, et al. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway［J］. J Biosci, 2012, 37(1): 91-101. ［18］ Aleksandrova K, Boeing H, Jenab M, et al. Leptin and soluble leptin receptor in risk of colorectal cancer in the European prospective investigation into cancer and nutrition cohort［J］. Cancer Res, 2012, 72(20): 5328-5337. ［19］ Jaffe T, Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signaltransduction pathways［J］. Int J Cancer, 2008, 123(11): 2543-2556. ［20］ Fazeli MS, Dashti H, Akbarzadeh S, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer［J］. Cytokine, 2013, 62(1): 81-85. ［21］ Zhang YY, Zhou LM. Omentin1, a new adipokine, promotes apoptosis through regulating Sirt1dependent p53 deacetylation in hepatocellular carcinoma cells［J］. Eur J Pharmacol, 2013, 698(1-3): 137-144. ［22］ Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin［J］. Science, 2005, 307(5708): 426-430. ［23］ Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer［J］. Cancer Sci, 2010, 101(5): 12861291. ［24］ Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer［J］. J Gastroenterol, 2009, 44(7): 685690. ［25］ Chen M, Wang Y, Li Y, et al. Association of plasma visfatin with risk of colorectal cancer: an observational study of Chinese patients［J］. Asia Pac J Clin Oncol, 2013, In press. ［26］ Huang WS, Chen CN, Sze CI, et al. Visfatin induces stromal cellderived factor1 expression by β1 integrin signaling in colorectal cancer cells［J］. J Cell Physiol, 2013, 228(5): 1017-1024. ［27］ Oita RC, Ferdinando D, Wilson S, et al. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Aktand MAPKindependent, NFκBdependent manner［J］. Pflugers Arch, 2010, 459(4): 619-630. ［28］ Park JW, Kim WH, Shin SH, et al. Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway［J］. Biochim Biophys Acta, 2011, 1813(5): 763-771.

[1]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	刘德宝, 孙子雯, 鲁守堂, 徐海东.ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[6]	陈卓, 陶俊, 陈琳, 柯晶.外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[7]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺.结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[8]	徐良富, 李袁飞.MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[9]	刘玉杰, 赵志强, 王子琤.早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[10]	陶红, 殷红, 罗宏, 陶佳瑜.靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[11]	王熙, 吴川清.结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.
[12]	高一钊, 刘洋, 刘秋龙, 邢金良.循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[13]	何哲锋, 吴燚阳, 李振军, 应晓江.炎性相关标志物对结直肠癌的预测价值[J]. 国际肿瘤学杂志, 2022, 49(9): 560-563.
[14]	赵莹, 张革红.AGR、PLR及NLR变化与转移性结直肠癌化疗疗效的相关性研究[J]. 国际肿瘤学杂志, 2022, 49(8): 473-477.
[15]	黄梦盼, 王学红, 芦永福.FOXA2在结直肠癌中的作用机制及其在诊疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(8): 490-493.